I think this is close to the low. This was a $6 stock back in the summer b4 their lung cancer drug trial failed. The partnership and deal with Novartis and their 6 endocrine portfolio + the streamlining and new laser focus of the company makes this a more exciting company imo. Way undervalued here.
News 
Market Data 
Discover 
